|Day's Range||159.84 - 165.27|
|52 Week Range||158.54 - 209.22|
|PE Ratio (TTM)||168.24|
|Dividend & Yield||0.91 (0.57%)|
|1y Target Est||N/A|
The chief executive of Shire has questioned investors' valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price. Flemming Ornskov also ...
The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire